Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Director | February 05, 2026 | February 06, 2026 |
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director · CEO | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 9,703 |
Reported balance
After 2026-02-05 transaction · row 1
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 5,663 · Balance 9,703 F1: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 517,290 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 8,724 · Balance 517,290 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 21:19 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 8,724 | $7.14 | $62,323.38 |
DisclosureSEC source: 0001613084-26-000004 · wk-form4_1788470363.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,290 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 23:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 19,181 | $11.76 | $225,499.51 |
DisclosureSEC source: 0001613084-26-000001 · wk-form4_1772580082.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,014 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 9,869 | $11.66 | $115,051.82 |
DisclosureSEC source: 0001613084-26-000001 · wk-form4_1772580082.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,195 F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 208,000 | $0.00 Strike: $11.93 | $0.00 |
DisclosureSEC source: 0001613084-26-000001 · wk-form4_1772580082.xml · derivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,000 Underlying: Common Stock · 208,000 shares Expires 2036-03-01 F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 139,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001613084-26-000001 · wk-form4_1772580082.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,064 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 22:46 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 5,663 | $27.85 | $157,714.55 |
DisclosureSEC source: 0001193125-26-041482 · ownership.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,703 F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:04 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 8,723 | $5.43 | $47,367.63 |
DisclosureSEC source: 0001613084-25-000003 · wk-form4_1757019877.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 415,664 F1 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:01 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 17,566 | $11.68 | $205,146.29 |
DisclosureSEC source: 0001689375-25-000015 · wk-form4_1741125701.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,387 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:01 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 173,400 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001689375-25-000015 · wk-form4_1741125701.xml · derivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,400 Underlying: Common Stock · 173,400 shares Expires 2035-03-01 F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:01 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 116,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-25-000015 · wk-form4_1741125701.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,953 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:10 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 4,040 | $52.32 | $211,372.80 |
DisclosureSEC source: 0000950170-25-017892 · ownership.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,040 F1 · shares: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. Read SEC document |
| September 05, 2024 Filed Sep 5, 2024 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 826 | $15.13 | $12,494.08 |
DisclosureSEC source: 0001689375-24-000052 · wk-form4_1725576578.xml · nonDerivative · entry 5 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,753 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 4,744 | $15.42 | $73,168.61 |
DisclosureSEC source: 0001689375-24-000052 · wk-form4_1725576578.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,579 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 72 | $17.70 | $1,274.54 |
DisclosureSEC source: 0001689375-24-000052 · wk-form4_1725576578.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,323 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 752 | $16.93 | $12,727.98 |
DisclosureSEC source: 0001689375-24-000052 · wk-form4_1725576578.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,395 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 2,328 | $15.76 | $36,691.84 |
DisclosureSEC source: 0001689375-24-000052 · wk-form4_1725576578.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,147 F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 20:42 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,600 | $17.81 | $28,497.28 |
DisclosureSEC source: 0001689375-24-000040 · wk-form4_1721162529.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,475 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.47 to $18.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 20:42 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 300 | $18.00 | $5,400.00 |
DisclosureSEC source: 0001689375-24-000040 · wk-form4_1721162529.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,075 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $16.17 | $16,173.60 |
DisclosureSEC source: 0001689375-24-000033 · wk-form4_1718397122.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,375 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.87 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 17, 2024 Filed May 20, 2024 21:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,200 | $15.11 | $18,129.12 |
DisclosureSEC source: 0001689375-24-000030 · wk-form4_1716240109.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,375 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,800 | $15.00 | $27,000.00 |
DisclosureSEC source: 0001689375-24-000030 · wk-form4_1716240109.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,575 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 00:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 5,049 | $12.28 | $61,995.66 |
DisclosureSEC source: 0001689375-24-000006 · wk-form4_1709686121.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,375 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,391 | $13.37 | $18,593.91 |
DisclosureSEC source: 0001689375-24-000006 · wk-form4_1709686121.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,424 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,164 | $12.42 | $14,460.37 |
DisclosureSEC source: 0001689375-24-000006 · wk-form4_1709686121.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,815 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 158,500 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001689375-24-000006 · wk-form4_1709686121.xml · derivative · entry 5 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,500 Underlying: Common Stock · 158,500 shares Expires 2034-03-01 F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2028. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:48 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 104,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-24-000006 · wk-form4_1709686121.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,979 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:37 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001689375-24-000002 · wk-form4_1708465024.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.99 | $15,990.00 |
DisclosureSEC source: 0001689375-24-000001 · wk-form4_1705613546.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:38 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001689375-23-000076 · wk-form4_1703281095.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| November 13, 2023 Filed Nov 13, 2023 21:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $16.23 | $16,230.00 |
DisclosureSEC source: 0001689375-23-000075 · wk-form4_1699911333.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 246,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 21:27 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001689375-23-000069 · wk-form4_1697750861.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 20:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.00 | $15,000.00 |
DisclosureSEC source: 0001689375-23-000066 · wf-form4_169480928381353.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 248,279 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 1,440 | $14.46 | $20,826.00 |
DisclosureSEC source: 0001689375-23-000065 · wf-form4_169403472503735.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,279 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 75,250 | $0.00 Strike: $15.41 | $0.00 |
DisclosureSEC source: 0001689375-23-000065 · wf-form4_169403472503735.xml · derivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,250 Underlying: Common Stock · 75,250 shares Expires 2033-09-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 49,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000065 · wf-form4_169403472503735.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,719 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $15.67 | $15,671.30 |
DisclosureSEC source: 0001689375-23-000056 · wf-form4_169221794370631.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,069 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.33 to $16.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2023 Filed May 1, 2023 20:38 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,000 | $13.71 | $27,421.80 |
DisclosureSEC source: 0001689375-23-000033 · wf-form4_168297348866904.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,069 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.42 to $14.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 22:07 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,092 | $18.01 | $37,675.25 |
DisclosureSEC source: 0001689375-23-000032 · wf-form4_168194205167642.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,069 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 200 | $15.51 | $3,102.00 |
DisclosureSEC source: 0001689375-23-000020 · wf-form4_168012433661989.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,811 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,800 | $14.63 | $26,333.28 |
DisclosureSEC source: 0001689375-23-000020 · wf-form4_168012433661989.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,011 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 3,324 | $11.60 | $38,545.77 |
DisclosureSEC source: 0001689375-23-000013 · wf-form4_167787923707368.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,811 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 150,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000013 · wf-form4_167787923707368.xml · derivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,500 Underlying: Common Stock · 150,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:34 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 99,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000013 · wf-form4_167787923707368.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,135 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:52 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 75,250 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000030 · wf-form4a_168194111990641.xml · derivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,250 Underlying: Common Stock · 75,250 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 150,500 option shares and 99,300 RSUs, when in fact 75,250 option shares and 49,650 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 75,250 option shares and 49,650 RSUs, respectively. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:52 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 49,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000030 · wf-form4a_168194111990641.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,161 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 150,500 option shares and 99,300 RSUs, when in fact 75,250 option shares and 49,650 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 75,250 option shares and 49,650 RSUs, respectively. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:36 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,000 | $12.00 | $24,000.00 |
DisclosureSEC source: 0001689375-23-000009 · wf-form4_167779297149606.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,835 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,000 | $12.00 | $24,001.00 |
DisclosureSEC source: 0001689375-23-000005 · wf-form4_167511434830711.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,835 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 21:40 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,410 | $15.02 | $36,195.55 |
DisclosureSEC source: 0001689375-23-000004 · wf-form4_167338679689446.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,835 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 29, 2022 Filed Dec 29, 2022 21:51 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 400 | $15.01 | $6,005.12 |
DisclosureSEC source: 0001689375-22-000050 · wf-form4_167235065224928.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,245 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2022 Filed Dec 29, 2022 21:51 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,521 | $15.01 | $67,851.62 |
DisclosureSEC source: 0001689375-22-000050 · wf-form4_167235065224928.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,645 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.